{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:08:51Z","timestamp":1777982931464,"version":"3.51.4"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.thromres.2022.01.001","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T08:26:09Z","timestamp":1653553569000},"page":"S103-S106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S1","title":["Optimizing antithrombotic therapy for atrial fibrillation in cancer"],"prefix":"10.1016","volume":"213","author":[{"given":"Antonella","family":"Tufano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.thromres.2022.01.001_bb0005","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"issue":"36","key":"10.1016\/j.thromres.2022.01.001_bb0010","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1093\/eurheartj\/ehw385","article-title":"Specific risk of atrial fibrillation and stroke in oncology patients","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2022.01.001_bb0015","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"The task force for cancer treatments and cardiovascular toxicity of the european Society of Cardiology (ESC). 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2022.01.001_bb0020","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ijcard.2012.08.036","article-title":"Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients","volume":"165","author":"Hu","year":"2013","journal-title":"Int. J. Cardiol."},{"issue":"2","key":"10.1016\/j.thromres.2022.01.001_bb0025","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/20009666.2020.1726571","article-title":"Atrial fibrillation and cancer; understanding the mysterious relationship through a systematic review","volume":"10","author":"Lateef","year":"2020","journal-title":"J. Community Hosp. Intern. Med. Perspect."},{"key":"10.1016\/j.thromres.2022.01.001_bb0030","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.ajem.2015.07.033","article-title":"Thirty-day mortality in ED patients with new onset atrial fibrillation and actively treated cancer","volume":"33","author":"Lardaro","year":"2015","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.thromres.2022.01.001_bb0035","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jacc.2013.11.026","article-title":"Insights into onco-cardiology: atrial fibrillation in cancer","volume":"63","author":"Farmakis","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2022.01.001_bb0040","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/europace\/eup300","article-title":"Introducing a new entity: chemotherapy-induced arrhythmia","volume":"11","author":"Guglin","year":"2009","journal-title":"Europace"},{"key":"10.1016\/j.thromres.2022.01.001_bb0045","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40264-014-0258-4","article-title":"Cancer chemotherapy and cardiac arrhythmias: a review","volume":"38","author":"Tamargo","year":"2015","journal-title":"Drug Saf."},{"issue":"2","key":"10.1016\/j.thromres.2022.01.001_bb0050","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nrcardio.2015.2","article-title":"Inflammation and the pathogenesis of atrial fibrillation","volume":"1","author":"Hu","year":"2015","journal-title":"Nat. Rev. Cardiol."},{"issue":"15","key":"10.1016\/j.thromres.2022.01.001_bb0055","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/eurheartj\/ehs181","article-title":"Cancer drugs and the heart: importance and management","volume":"34","author":"Suter","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2022.01.001_bb0060","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1200\/JCO.1991.9.1.192","article-title":"Cisplatin-induced atrial fibrillation","volume":"9","author":"Menard","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2022.01.001_bb0065","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1158\/1078-0432.CCR-04-2602","article-title":"The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial","volume":"11","author":"Lara","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.thromres.2022.01.001_bb0070","first-page":"53","article-title":"Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade","volume":"12","author":"Tomkowski","year":"2004","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.thromres.2022.01.001_bb0075","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1200\/JCO.2005.04.6813","article-title":"Phase I to II study of pleurectomy\/ decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma","volume":"24","author":"Richards","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2022.01.001_bb0080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.7326\/0003-4819-118-1-199301010-00006","article-title":"High-dose ifosfamide is associated with severe, reversible cardiac dysfunction","volume":"118","author":"Quezado","year":"1993","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.thromres.2022.01.001_bb0085","first-page":"91","article-title":"Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings","volume":"5","author":"Kupari","year":"1990","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.thromres.2022.01.001_bb0090","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/sj.bmt.1701763","article-title":"Melphalan 220 mg\/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma","volume":"23","author":"Moreau","year":"1999","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.thromres.2022.01.001_bb0095","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/sj.bmt.1701217","article-title":"Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cells","volume":"21","author":"Olivieri","year":"1998","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.thromres.2022.01.001_bb0100","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/clc.20904","article-title":"Melphalan-induced supraventricular tachycardia: incidence and risk factors","volume":"34","author":"Feliz","year":"2011","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.thromres.2022.01.001_bb0105","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.bbmt.2004.03.001","article-title":"Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study","volume":"10","author":"Phillips","year":"2004","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.thromres.2022.01.001_bb0110","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1080\/10428190500235884","article-title":"Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stern cell transplantation for patients aged 60 years and older","volume":"45","author":"Mileshkin","year":"2005","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.thromres.2022.01.001_bb0115","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00432-007-0250-9","article-title":"Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study","volume":"134","author":"Kosmas","year":"2008","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.thromres.2022.01.001_bb0120","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0167-8140(88)90296-4","article-title":"Adverse cardiac effects during induction chemotherapy treatment with cisplatin and 5-fluorouracil","volume":"13","author":"Eskilsson","year":"1988","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.thromres.2022.01.001_bb0125","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1080\/1120009X.1990.11739029","article-title":"Cardiotoxicity during chemotherapy treatment with 5-fluorouracil and cisplatin","volume":"2","author":"Jeremic","year":"1990","journal-title":"J. Chemother."},{"key":"10.1016\/j.thromres.2022.01.001_bb0130","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/bmj.39507.551644.BE","article-title":"Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population-based case-control study","volume":"336","author":"S\u00f8rensen","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2022.01.001_bb0135","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2022.01.001_bb0140","doi-asserted-by":"crossref","first-page":"E312","DOI":"10.1002\/ajh.24366","article-title":"Atrial fibrillation associated with ibrutinib in Waldenstrom\u2019s macroglobulinemia","volume":"91","author":"Gustine","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.thromres.2022.01.001_bb0145","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","volume":"17","author":"Chanan-Khan","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.thromres.2022.01.001_bb0150","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","article-title":"European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma","volume":"18","author":"Foran","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2022.01.001_bb0155","first-page":"157","article-title":"Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study","volume":"3","author":"Dutcher","year":"1997","journal-title":"Cancer J. Sci. Am."},{"key":"10.1016\/j.thromres.2022.01.001_bb0160","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1093\/annonc\/mdm489","article-title":"Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma","volume":"18","author":"Mego","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.thromres.2022.01.001_bb0165","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/annonc\/mdu212","article-title":"A phase I\/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma","volume":"25","author":"Rini","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.thromres.2022.01.001_bb0170","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00228-007-0328-y","article-title":"New onset of atrial fibrillation after introduction of azathioprine in ulcerative colitis: case report and review of the literature","volume":"63","author":"Cassinotti","year":"2007","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.thromres.2022.01.001_bb0175","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/bmj.291.6497.706","article-title":"Fast atrial fibrillation induced by treatment of psoriasis with azathioprine","volume":"291","author":"Dodd","year":"1985","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2022.01.001_bb0180","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/bmj.291.6501.1049-a","article-title":"Fast atrial fibrillation induced by azathioprine","volume":"291","author":"Murphy","year":"1985","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2022.01.001_bb0185","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/039463201102400131","article-title":"Recurrent atrial fibrillation in a patient with ulcerative colitis treated with azathioprine: case report and review of the literature","volume":"24","author":"Riccioni","year":"2011","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.thromres.2022.01.001_bb0190","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1177\/030089160208800618","article-title":"Atrial fibrillation during adjuvant chemotherapy with docetaxel: a case report","volume":"88","author":"Palma","year":"2002","journal-title":"Tumori"},{"key":"10.1016\/j.thromres.2022.01.001_bb0195","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000087242","article-title":"Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis","volume":"54","author":"Zingler","year":"2005","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.thromres.2022.01.001_bb0200","doi-asserted-by":"crossref","DOI":"10.1111\/j.1524-4741.2007.00408.x","article-title":"Non-myopathic cardiac events in two patients treated with trastuzumab","volume":"13","author":"Olin","year":"2007","journal-title":"Breast J."},{"key":"10.1016\/j.thromres.2022.01.001_bb0205","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ijcard.2017.03.132","article-title":"Atrial fibrillation in cancer patients: hindsight, insight and foresight","volume":"240","author":"Mery","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.thromres.2022.01.001_bb0210","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.blre.2015.07.001","article-title":"The prothrombotic activity of cancer cells in the circulation","volume":"30","author":"Mitrugno","year":"2016","journal-title":"Blood Rev."},{"issue":"1","key":"10.1016\/j.thromres.2022.01.001_bb0215","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11739-018-1956-1","article-title":"Position paper of the italian Society of Internal Medicine (SIMI) on prophylaxis and treatment of venous thromboembolism in patients with cancer","volume":"14","author":"Prisco","year":"2019","journal-title":"Intern. Emerg. Med."},{"issue":"4","key":"10.1016\/j.thromres.2022.01.001_bb0220","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1055\/s-0038-1648229","article-title":"Anticancer drug-related nonvalvular atrial fibrillation: challenges in management and antithrombotic strategies","volume":"44","author":"Tufano","year":"2018","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2022.01.001_bb0225","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1634\/theoncologist.2013-0239","article-title":"New oral anticoagulants and the cancer patient","volume":"19","author":"Short","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.thromres.2022.01.001_bb0230","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ijcard.2015.10.166","article-title":"Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy","volume":"203","author":"Lee","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.thromres.2022.01.001_bb0235","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.thromres.2016.05.028","article-title":"The impact of new-onset cancer among veterans who are receiving warfarin for atrial fibrillation and venous thromboembolism","volume":"144","author":"Ambrus","year":"2016","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2022.01.001_bb0240","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2022.01.001_bb0245","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2022.01.001_bb0250","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.thromres.2017.05.006","article-title":"Cancer, atrial fibrillation, and stroke","volume":"155","author":"Fitzpatrick","year":"2017","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2022.01.001_bb0255","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1160\/TH08-12-0832","article-title":"Anti-cancer properties of low-molecular-weight heparin: preclinical evidence","volume":"102","author":"Mousa","year":"2009","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.01.001_bb0260","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an Oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2022.01.001_bb0265","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2022.01.001_bb0270","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.thromres.2022.01.001_bb0275","doi-asserted-by":"crossref","first-page":"162","DOI":"10.21037\/atm-20-8156","article-title":"Treatment of venous thromboembolism in cancer patients: a systematic review and meta-analysis on the efficacy and safety of different direct oral anticoagulants (DOACs)","volume":"9","author":"Song","year":"2021","journal-title":"Ann. Transl. Med."},{"issue":"10","key":"10.1016\/j.thromres.2022.01.001_bb0280","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"10.1016\/j.thromres.2022.01.001_bb0285","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/cam4.1054","article-title":"Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a danish nationwide population-based cohort study","volume":"6","author":"Ording","year":"2017","journal-title":"Cancer Med."},{"key":"10.1016\/j.thromres.2022.01.001_bb0290","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.amjmed.2017.06.026","article-title":"Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE trial","volume":"130","author":"Melloni","year":"2017","journal-title":"Am. J. Med."},{"key":"10.1016\/j.thromres.2022.01.001_bb0295","doi-asserted-by":"crossref","first-page":"92","DOI":"10.7150\/jca.36468","article-title":"Novel oral anticoagulant versus warfarin in cancer patients with atrial fibrillation: an 8-year population-based cohort study","volume":"11","author":"Wu","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.thromres.2022.01.001_bb0300","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/bloodadvances.2017010694","article-title":"Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation","volume":"2","author":"Shah","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.thromres.2022.01.001_bb0305","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012540","article-title":"Non-vitamin K antagonist oral anticoagulants versus warfarin in patients with cancer and atrial fibrillation: a systematic review and meta-analysis","volume":"8","author":"Deng","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.thromres.2022.01.001_bb0310","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1055\/s-0039-3400300","article-title":"Efficacy and safety of nonvitamin K oral anticoagulants in patients with atrial fibrillation and cancer: a study-level metaanalysis","volume":"120","author":"Cavallari","year":"2020","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.01.001_bb0315","first-page":"706","article-title":"Superior safety of direct oral anticoagulants compared to warfarin in patients with atrial fibrillation and underlying cancer: a national veterans affairs database study","volume":"16","author":"Sawant","year":"2019","journal-title":"J. Geriatr. Cardiol."},{"issue":"4","key":"10.1016\/j.thromres.2022.01.001_bb0320","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/joim.13092","article-title":"Use of oral anticoagulants after ischaemic stroke in patients with atrial fibrillation and cancer","volume":"288","author":"Atterman","year":"2020","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.thromres.2022.01.001_bb0325","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.pcad.2021.04.004","article-title":"Cancer and atrial fibrillation: epidemiology, mechanisms, and anticoagulation treatment","volume":"66","author":"Menichelli","year":"2021","journal-title":"Prog. Cardiovasc. Dis."},{"key":"10.1016\/j.thromres.2022.01.001_bb0330","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1742-1241.2009.02286.x","article-title":"Drug and dietary interactions of the new and emerging oral anticoagulants","volume":"64","author":"Walenga","year":"2010","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.thromres.2022.01.001_bb0335","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood-2014-07-590323","article-title":"The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analyses","volume":"124","author":"Chai-Adisaksopha","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2022.01.001_bb0340","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/cpt.419","article-title":"Ibrutinib dosing strategies based on interaction potential of CYP3A4 perpetrators using physiologically based pharmacokinetic modeling","volume":"100","author":"de Zwart","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.thromres.2022.01.001_bb0345","article-title":"Atrial fibrillation and cancer","volume":"15","author":"Hajjar","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.thromres.2022.01.001_bb0350","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/jth.14478","article-title":"Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: guidance from the SSC of the ISTH","volume":"17","author":"Delluc","year":"2019","journal-title":"J. Thromb. Haemost."},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2022.01.001_bb0355","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/S0049-3848(20)30400-X","article-title":"Anticoagulant and antiplatelet treatment in cancer patients with thrombocytopenia","volume":"191","author":"Leader","year":"2020","journal-title":"Thromb. Res."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384822000019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384822000019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:48:31Z","timestamp":1758736111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384822000019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":71,"alternative-id":["S0049384822000019"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2022.01.001","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing antithrombotic therapy for atrial fibrillation in cancer","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2022.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}